Cargando…

Variation in Adherence Measures to Imatinib Therapy

PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanamandra, Uday, Malhotra, Pankaj, Sahu, K.K., Sushma, Yanamandra, Saini, Neha, Chauhan, Pooja, Gill, Jasmeen, Rikhi, Deepika, Khadwal, Alka, Prakash, Gaurav, Lad, Deepesh, Suri, Vikas, Kumari, Savita, Varma, Neelam, Varma, Subhash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223484/
https://www.ncbi.nlm.nih.gov/pubmed/30241224
http://dx.doi.org/10.1200/JGO.2016.007906
_version_ 1783369414619430912
author Yanamandra, Uday
Malhotra, Pankaj
Sahu, K.K.
Sushma, Yanamandra
Saini, Neha
Chauhan, Pooja
Gill, Jasmeen
Rikhi, Deepika
Khadwal, Alka
Prakash, Gaurav
Lad, Deepesh
Suri, Vikas
Kumari, Savita
Varma, Neelam
Varma, Subhash
author_facet Yanamandra, Uday
Malhotra, Pankaj
Sahu, K.K.
Sushma, Yanamandra
Saini, Neha
Chauhan, Pooja
Gill, Jasmeen
Rikhi, Deepika
Khadwal, Alka
Prakash, Gaurav
Lad, Deepesh
Suri, Vikas
Kumari, Savita
Varma, Neelam
Varma, Subhash
author_sort Yanamandra, Uday
collection PubMed
description PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. PATIENTS AND METHODS: This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician’s assessment. JMP 13.0.0 was used for statistical analysis. RESULTS: A total of 333 patients with a median age of 42 years were included in the study. The median BCR-ABL/ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 11 ± 2. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician’s assessment reported adherence in 90.39% of patients. Using the χ(2) test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician’s assessment and MMAS-9 (P < .001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), χ(2) (1,220) = 135.45 (P < .001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence (P = .012). CONCLUSION: This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level.
format Online
Article
Text
id pubmed-6223484
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-62234842018-11-13 Variation in Adherence Measures to Imatinib Therapy Yanamandra, Uday Malhotra, Pankaj Sahu, K.K. Sushma, Yanamandra Saini, Neha Chauhan, Pooja Gill, Jasmeen Rikhi, Deepika Khadwal, Alka Prakash, Gaurav Lad, Deepesh Suri, Vikas Kumari, Savita Varma, Neelam Varma, Subhash J Glob Oncol ORIGINAL REPORTS PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. PATIENTS AND METHODS: This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician’s assessment. JMP 13.0.0 was used for statistical analysis. RESULTS: A total of 333 patients with a median age of 42 years were included in the study. The median BCR-ABL/ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 11 ± 2. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician’s assessment reported adherence in 90.39% of patients. Using the χ(2) test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician’s assessment and MMAS-9 (P < .001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), χ(2) (1,220) = 135.45 (P < .001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence (P = .012). CONCLUSION: This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level. American Society of Clinical Oncology 2017-03-24 /pmc/articles/PMC6223484/ /pubmed/30241224 http://dx.doi.org/10.1200/JGO.2016.007906 Text en © 2017 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Yanamandra, Uday
Malhotra, Pankaj
Sahu, K.K.
Sushma, Yanamandra
Saini, Neha
Chauhan, Pooja
Gill, Jasmeen
Rikhi, Deepika
Khadwal, Alka
Prakash, Gaurav
Lad, Deepesh
Suri, Vikas
Kumari, Savita
Varma, Neelam
Varma, Subhash
Variation in Adherence Measures to Imatinib Therapy
title Variation in Adherence Measures to Imatinib Therapy
title_full Variation in Adherence Measures to Imatinib Therapy
title_fullStr Variation in Adherence Measures to Imatinib Therapy
title_full_unstemmed Variation in Adherence Measures to Imatinib Therapy
title_short Variation in Adherence Measures to Imatinib Therapy
title_sort variation in adherence measures to imatinib therapy
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223484/
https://www.ncbi.nlm.nih.gov/pubmed/30241224
http://dx.doi.org/10.1200/JGO.2016.007906
work_keys_str_mv AT yanamandrauday variationinadherencemeasurestoimatinibtherapy
AT malhotrapankaj variationinadherencemeasurestoimatinibtherapy
AT sahukk variationinadherencemeasurestoimatinibtherapy
AT sushmayanamandra variationinadherencemeasurestoimatinibtherapy
AT sainineha variationinadherencemeasurestoimatinibtherapy
AT chauhanpooja variationinadherencemeasurestoimatinibtherapy
AT gilljasmeen variationinadherencemeasurestoimatinibtherapy
AT rikhideepika variationinadherencemeasurestoimatinibtherapy
AT khadwalalka variationinadherencemeasurestoimatinibtherapy
AT prakashgaurav variationinadherencemeasurestoimatinibtherapy
AT laddeepesh variationinadherencemeasurestoimatinibtherapy
AT surivikas variationinadherencemeasurestoimatinibtherapy
AT kumarisavita variationinadherencemeasurestoimatinibtherapy
AT varmaneelam variationinadherencemeasurestoimatinibtherapy
AT varmasubhash variationinadherencemeasurestoimatinibtherapy